Xenetic Biosciences, Inc. Warrants
XBIOW
XBIOW was delisted on the 16th of July, 2024.
1 hedge funds and large institutions have $2.95K invested in Xenetic Biosciences, Inc. Warrants in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $3K → $2.95K (-$46)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$88 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $2.95K | +$88 | +100 | +7% |
|
XBIOW Hedge Fund Activity: Q4 2022 in Review
1 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences, Inc. Warrants (XBIOW) for Q4 2022, worth a combined $2.95K — down 1.5% from $3K a quarter earlier.
Fund positioning in XBIOW was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $88.
- 1 institutional investor held Xenetic Biosciences, Inc. Warrants (XBIOW) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $2.95K of Xenetic Biosciences, Inc. Warrants stock for Q4 2022, down 1.5% quarter-over-quarter.
- 0 funds opened new Xenetic Biosciences, Inc. Warrants positions in Q4 2022 and 0 closed out.
- The largest Xenetic Biosciences, Inc. Warrants buyer in Q4 2022 was UBS Group, an estimated $88 added.
Based on aggregated 13F filings for Q4 2022.